Khadijah Breathett1, Shannon Willis2, Randi E Foraker3, Sakima Smith4. 1. Division of Cardiology, University of Colorado Anschutz Medical Center, Aurora, Colorado. Electronic address: Khadijah.breathett@ucdenver.edu. 2. Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio. 3. Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio. 4. Division of Cardiology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Abstract
BACKGROUND: Heart transplantation allocation is often restricted from patients with low socioeconomic status (SES) due to concern for worse outcomes. We hypothesised that comorbidities would have a greater impact on risk of severe rejection post-orthotopic heart transplant than would Medicaid insurance and Median Household Income (MHI). METHODS: A retrospective study of 171 patients who underwent orthotopic heart transplant between 7/1999-11/2013 at our facility were followed until 9/2014 for rejection hospitalisations or death. Survival and multivariable analyses with adjustment for age, race, and gender were performed to estimate the risk of severe cellular rejection, ≥2r (hazard ratio [HR], 95% confidence interval [CI]). RESULTS: Eighteen per cent of patients had Medicaid, and 72% of patients had low or medium MHI. Severe rejection occurred in 23% of patients. In the univariable analysis, Medicaid and diabetes were associated with increased risk of rejection while age >60 years, Caucasian race, and male sex were associated with reduced risk [Medicaid 2.32(1.20,4.51), diabetes 2.49(1.09,5.69), age 0.41(0.20,0.84), Caucasian 0.44(0.21,0.93), male 0.49(0.26,0.92)]. Median Household Income had no correlation [MHI 0.79(0.51,1.23)]. In the multivariable adjusted model, Medicaid was not associated with rejection [1.65(0.79,3.41)]; diabetes was strongly associated with risk of severe rejection [3.9(1.59,9.39)], and age >60 years was associated with risk reduction [0.42(0.20,0.82)]. CONCLUSIONS: Medicaid insurance and MHI were not associated with increased risk of severe cellular rejection requiring hospitalisation post-orthotopic heart transplant in the adjusted model. Rather the presence of diabetes and age ≤60 years were associated with increased risk.
BACKGROUND: Heart transplantation allocation is often restricted from patients with low socioeconomic status (SES) due to concern for worse outcomes. We hypothesised that comorbidities would have a greater impact on risk of severe rejection post-orthotopic heart transplant than would Medicaid insurance and Median Household Income (MHI). METHODS: A retrospective study of 171 patients who underwent orthotopic heart transplant between 7/1999-11/2013 at our facility were followed until 9/2014 for rejection hospitalisations or death. Survival and multivariable analyses with adjustment for age, race, and gender were performed to estimate the risk of severe cellular rejection, ≥2r (hazard ratio [HR], 95% confidence interval [CI]). RESULTS: Eighteen per cent of patients had Medicaid, and 72% of patients had low or medium MHI. Severe rejection occurred in 23% of patients. In the univariable analysis, Medicaid and diabetes were associated with increased risk of rejection while age >60 years, Caucasian race, and male sex were associated with reduced risk [Medicaid 2.32(1.20,4.51), diabetes 2.49(1.09,5.69), age 0.41(0.20,0.84), Caucasian 0.44(0.21,0.93), male 0.49(0.26,0.92)]. Median Household Income had no correlation [MHI 0.79(0.51,1.23)]. In the multivariable adjusted model, Medicaid was not associated with rejection [1.65(0.79,3.41)]; diabetes was strongly associated with risk of severe rejection [3.9(1.59,9.39)], and age >60 years was associated with risk reduction [0.42(0.20,0.82)]. CONCLUSIONS: Medicaid insurance and MHI were not associated with increased risk of severe cellular rejection requiring hospitalisation post-orthotopic heart transplant in the adjusted model. Rather the presence of diabetes and age ≤60 years were associated with increased risk.
Authors: Jeremiah G Allen; Eric S Weiss; George J Arnaoutakis; Stuart D Russell; William A Baumgartner; Ashish S Shah; John V Conte Journal: J Heart Lung Transplant Date: 2011-10-01 Impact factor: 10.247
Authors: M Grimm; M Rinaldi; N A Yonan; G Arpesella; J M Arizón Del Prado; L A Pulpón; J P Villemot; M Frigerio; J L Rodriguez Lambert; M G Crespo-Leiro; L Almenar; D Duveau; A Ordonez-Fernandez; J Gandjbakhch; M Maccherini; G Laufer Journal: Am J Transplant Date: 2006-06 Impact factor: 8.086
Authors: Randi E Foraker; Mehul D Patel; Eric A Whitsel; Chirayath M Suchindran; Gerardo Heiss; Kathryn M Rose Journal: Am Heart J Date: 2012-11-20 Impact factor: 4.749
Authors: Luit Penninga; Christian H Møller; Finn Gustafsson; Daniel A Steinbrüchel; Christian Gluud Journal: Eur J Clin Pharmacol Date: 2010-09-30 Impact factor: 2.953
Authors: J A Kobashigawa; J K Kirklin; D C Naftel; R C Bourge; H O Ventura; P K Mohanty; G B Cintron; G Bhat Journal: J Heart Lung Transplant Date: 1993 May-Jun Impact factor: 10.247
Authors: Salpy V Pamboukian; Maria Rosa Costanzo; Peter Meyer; Linda Bartlett; Mary McLeod; Alain Heroux Journal: J Card Fail Date: 2003-04 Impact factor: 5.712
Authors: Dmitry Tumin; Jessica Horan; Emily A Shrider; Sakima A Smith; Joseph D Tobias; Don Hayes; Randi E Foraker Journal: Am Heart J Date: 2017-06-03 Impact factor: 4.749
Authors: Mary Amanda Dew; Andrea F DiMartini; Fabienne Dobbels; Kathleen L Grady; Sheila G Jowsey-Gregoire; Annemarie Kaan; Kay Kendall; Quincy-Robyn Young Journal: Curr Heart Fail Rep Date: 2019-12